NYSE:MDT

Medtronic Inc (MDT)

83.29
+0.09 (0.11%)
as of Jul 20, 2026, 8:00:00 pm Market Open.
182 watching
0
Investor Insights
star iconJul 20, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Medtronic Inc (MDT-N) has garnered a mix of opinions from experts. One expert sees the company benefiting from advancements in AI technologies, suggesting that boomers continuing to operate in the market serves as a tailwind for growth. Another expert expresses a more cautious outlook, highlighting that while MDT is currently experiencing a positive short- to medium-term phase and is positioned to compete strongly against peers like Boston Scientific, it may lack the research and development prowess to sustain its leadership over the long term. Despite being diversified in its product offerings, which is a strength compared to competitors focused solely on specific device categories, there are concerns about MDT's market position. Upcoming product launches and a perceived undervaluation, with the stock's price-to-earnings ratio being attractive, may support the stock for the next 12-18 months; however, the long-term outlook remains uncertain.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Undervalued
review icon
Similar
SYK
COMMENT

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

PAST TOP PICK

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

WEAK BUY

They have struggled over the most recent years after being a darling. There is the question of how healthcare will be paid for in the US. Device companies have the hardest headwinds. They are also in a very competitive area. It is not expensive and is a perfectly good way to be in the health care area. Their struggles may mean they have more upside potential if the healthcare sector improves.

PAST TOP PICK

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

DON'T BUY

There has been some major earnings volatility around this one recently. So he has backed off. They have a mid- to high- single digit earnings growth rate, but you are paying twice that. The PE to growth rate is too high. You are paying top dollar for the growth you are getting.

COMMENT

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

PAST TOP PICK

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

COMMENT

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

DON'T BUY

Seasonally, this doesn’t do too well at this time of year. That is pretty common for all the healthcare instrument stocks in general. Technically it is developing a downward trend and recently broke 2 support levels.

TOP PICK

A medical device business, one of the largest in the world. A very diverse product line. Valuation at about 18X earnings, the high end of the range, but medical devices are trading at a premium to Pharma. He sees single digit revenue growth and double digit earnings growth, and expects some real growth to come out of things like aortic valve replacement. Dividend yield of 2.07%.

HOLD

Has a target price of $98, so there is decent upside to it. They are talking about launching a robotic surgery system, so that is something to keep an eye on. It is not at the top of his list, so he wouldn’t be adding to it here.

TOP PICK

In general he has been cautious on Biotechs, but this is a medical devices company. It is very, very solid. In the next 5 years it should be growing revenues at mid-single digits. Earnings at low double digits. Dividend yield of 1.96%.

COMMENT

The medical device companies have done a lot better this year, versus pharmaceutical companies. If you are buying shares of a healthcare company right now, he would buy a pharmaceutical name or his Top Pick at the end. (See Top Picks.)

TOP PICK

A healthcare company, but not a pharmaceutical company. They are very big in cardiovascular and diabetes. Growing their top line at roughly 5%-10% per annum, and the bottom line closer to 12%-13% for the foreseeable future for the next 4-5 years. They are in the right place at the right time, and are likely to return about $1 billion a year to the shareholders for the next few years. They are committed to increasing their dividends. Dividend yield of 1.98%.

PAST TOP PICK

(Top Pick May 13/16, Down 9%) They gave positive guidance last earnings report. Healthcare stocks are starting to work over the last two to three weeks.

Showing 61 to 75 of 125 entries